

1 **The Proteome Landscape of Human Placentas for**
2 **Monochorionic Twins with Selective Intrauterine Growth**
3 **Restriction**

4

5 Xin-Lu Meng^{1,#}, Peng-Bo Yuan^{1,#}, Xue-Ju Wang¹, Jing Hang^{2,3,4,5}, Xiao-Ming Shi¹,
6 Yang-Yu Zhao^{1,*}, Yuan Wei^{1,*}

7

8 ¹ *Department of Obstetrics and Gynecology, Peking University Third Hospital,*
9 *Beijing 100191, China*

10 ² *Center for Reproductive Medicine, Department of Obstetrics and Gynecology,*
11 *Peking University Third Hospital, Beijing 100191, China*

12 ³ *Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing 100191,*
13 *China*

14 ⁴ *Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproduction,*
15 *Beijing 100191, China*

16 ⁵ *National Clinical Research Center for Obstetrics and Gynecology, Beijing 100191,*
17 *China*

18

19 # Equal contribution.

20 * Corresponding authors.

21 E-mail: weiyuanbysy@163.com (Wei Y), zhaoyangyu@bjmu.edu.cn (Zhao YY).

22

23 **Abstract**

24 In perinatal medicine, intrauterine growth restriction (IUGR) is one of the greatest
25 challenges. The etiology of IUGR is multifactorial, but most cases are thought to arise
26 from placental insufficiency. However, identifying the placental cause of IUGR can
27 be difficult due to numerous confounding factors. Selective IUGR (sIUGR) would be
28 a good model to investigate how impaired placentation affects fetal development, as
29 the growth discordance between monochorionic twins cannot be explained by
30 confounding genetic or maternal factors. Herein we constructed and analyzed the
31 placental proteomic profiles of IUGR twins and the normal cotwins. Specifically, we
32 identified a total of 5481 proteins and 233 differentially expressed proteins (DEPs),
33 including 57 upregulated and 176 downregulated DEPs in IUGR twins. Bioinformatic
34 analysis indicates that these DEPs are mainly associated with cardiovascular system
35 development and function, organismal survival, and organismal development. Notably,
36 34 DEPs are significantly enriched in angiogenesis, and diminished placental
37 angiogenesis in IUGR twins has been further elaborately confirmed. Moreover, we
38 found decreased expression of *metadherin* (*MTDH*) in placentas for IUGR twins and
39 demonstrated that *MTDH* contributes to placental angiogenesis and fetal growth *in*
40 *vitro*. Collectively, our findings reveal the comprehensive proteomic signature of
41 placentas for sIUGR twins, and the DEPs identified may provide in-depth insights
42 into pathogenesis of placental dysfunction and subsequent impaired fetal growth.

43

44 **KEYWORDS:** Selective intrauterine growth restriction; Placenta; Proteome;
45 Angiogenesis; *Metadherin*

46

47 **Introduction**

48 Intrauterine growth restriction (IUGR), which refers to the inability of the fetus to
49 reach its full growth potential, is among the most common pregnancy complications
50 and affects 7% of pregnancies worldwide [1]. Besides contributing to significant
51 perinatal and pediatric morbidity and mortality, it can also raise the risk of developing
52 metabolic, cardiovascular, and respiratory disorders later in life [2,3]. Despite the
53 involvement of multiple factors, placental insufficiency has been reported as a major
54 cause of IUGR [4,5]. Placental insufficiency refers to a process of progressive
55 deterioration of placental function. It reduces transplacental oxygen and nutrients
56 transfer to the growing fetus, and ultimately limits placental performance during
57 pregnancy [6,7]. However, identifying the molecular mechanisms underlying
58 pathogenesis of placental insufficiency is challenging due to the interference of
59 numerous maternal and genetic confounding factors.

60 Selective IUGR (sIUGR) is a unique complication of monochorionic (MC) twins
61 in which one twin is an IUGR fetus and the cotwin grows normally. An estimated
62 10%–15% of MC pregnancies suffer from it [8]. Several studies have extensively
63 investigated the development of sIUGR at the gross histopathological level and have
64 shown that sIUGR is associated with a remarkable discordance of placental sharing
65 wherein the IUGR twin is supported by a smaller portion of the placenta. Also, a
66 higher incidence of abnormal cord insertion occurs in the smaller fetuses [9,10].
67 Additionally, the terminal branch levels of the placental artery and vein were
68 significantly lower in the IUGR twins [11]. Together, these morphological alterations
69 suggest placental insufficiency and impaired blood perfusion to the fetus in sIUGR.
70 The two fetuses harbor an identical genotype and share the same maternal
71 environment. Thus, sIUGR twins would provide an ideal model to investigate the
72 underlying mechanisms of placental insufficiency by using the healthy cotwin as an
73 internal control to eliminate confounding maternal and genetic factors and to ensure
74 the same gestational age. Recent studies have found that dysregulation of several
75 angiogenesis-related genes, such as *endoglin* and *fms-like tyrosine kinase 1 (FLT1)*,

76 may contribute to the development of sIUGR [12–14]. The *hypoxia inducible*
77 *factor-1a (HIF1A)* mRNA levels, as well as 8-hydroxydeoxyguanosine (8-OHdG) and
78 malondialdehyde (MDA), both biomarkers of oxidative stress, have been
79 demonstrated to be significantly upregulated in IUGR twin placentas, suggesting that
80 oxidative stress might participate in the pathogenesis of sIUGR [15]. In other studies,
81 abnormal placental epigenetic modification, such as altered imprinted genes and DNA
82 methylation, has been found to cause sIUGR [16,17]. However, a systematic placental
83 proteomic profile linked with the functional analysis of clinical sIUGR is still absent.

84 In this study, we systematically investigated the placental proteome differences
85 between IUGR twins and the normal cotwins utilizing tandem mass tag (TMT)-based
86 technology. In total, we identified 5481 proteins and 233 differentially expressed
87 proteins (DEPs), of which 57 were upregulated and 176 were downregulated.
88 Bioinformatic analysis by ingenuity pathway analysis (IPA) revealed that these DEPs
89 were most significantly enriched in cardiovascular system development and function,
90 as well as organismal survival and organismal development. Notably, 34 DEPs were
91 associated with the biological process of angiogenesis, and we found that
92 angiogenesis was significantly impaired in IUGR twin placentas. The differential
93 expression of *ephrin B2 (EFNB2)*, *vimentin (VIM)* and *methionyl aminopeptidase 2*
94 (*METAP2*), which are essential in placental angiogenesis, was validated by PCR and
95 immunohistochemistry analysis. In addition, we found that *metadherin (MTDH)* was
96 significantly downregulated in IUGR twin placentas. Knockdown of *MTDH* in human
97 umbilical vein endothelial cells (HUVECs) obviously inhibited the proliferation,
98 migration, tube formation, and spheroid sprouting by affecting numerous genes and
99 biological processes. In brief, our study is the first comprehensive analysis of the
100 placental proteomic profile in sIUGR twins and may offer deeper insights into the
101 molecular mechanisms of IUGR.

102

103 **Results**

104 **Clinical characteristics**

105 To identify novel candidate molecules for sIUGR, we harvested 12 placental samples
106 from six sIUGR twin pairs and performed TMT-based comparative proteomic
107 analysis. sIUGR twins, which share the maternal environment and harbor an identical
108 genotype, provide an ideal model for investigating the association between placental
109 development and fetal growth. The demographics and clinical characteristics of the
110 twin pregnancies in this study are presented in Table S1 and Figure S1A–D. All twins
111 were delivered alive by cesarean section at a mean gestational age of 32.3 ± 1.2 weeks.
112 The birth weight of the IUGR twins was, on average, 628 grams lower than that of
113 their healthy cotwins ($P = 0.0004$), with relative birth weight discordance ranging
114 from 25.2% to 48.0%. None of the study population had twin-to-twin transfusion
115 syndrome, fetal malformations, and maternal complications such as preeclampsia or
116 diabetes mellitus. In addition, IUGR twin placentas exhibited more pathological
117 abnormalities, including distal villous hypoplasia, intervillous fibrin deposition,
118 increased syncytial knots, and abnormal cord insertion. (Figure S1E–I).

119 **Comparative proteomic analysis identifies 233 DEPs in IUGR twin placentas**

120 To comprehensively profile the global placental proteomic changes between IUGR
121 twins and normal cotwins, we applied a high-accuracy quantitative proteomic
122 approach to analyze protein expression (**Figure 1A**). A total of 12 samples from 6
123 pairs of sIUGR twins were processed in the same experimental period. After protein
124 extraction, reduction, alkylation, and digestion, each 3 pairs of sIUGR twins were
125 labeled with one set of six-plex TMT reagent (group 1: TMT 126, 127, and 128 for
126 normal cotwin 1, 2, and 3; TMT 129, 130, and 131 for IUGR twin 1, 2, and 3
127 respectively; group 2: TMT 126, 127, and 128 for normal cotwin 4, 5, and 6; TMT
128 129, 130, and 131 for IUGR twin 4, 5, and 6 respectively). Six isobaric labeled
129 samples within the same set were mixed together and then separated into 10 fractions
130 by high pH reversed-phase liquid chromatography (RPLC). All 20 fractions from two
131 TMT sets were subjected sequentially to liquid chromatography tandem mass
132 spectrometry (LC-MS/MS). MS data were then collected and analyzed for protein
133 identification and quantification. Details on MS data analysis were presented in the
134 Methods section. Specifically, we identified a total of 5481 nonredundant proteins in

135 sIUGR twin placentas (Table S2). A histogram plot revealed the fold change (FC)
136 distribution of all identified proteins (Figure 1B). The distribution of statistical
137 significance ($-\log_{10}$ transformed P value) and degree of change (\log_2 transformed FC)
138 for all identified proteins were presented in the volcano plot (Figure 1C). Using a
139 combination of $P < 0.05$ and $|FC| > 1.3$, 233 proteins displayed significant differential
140 expression in IUGR twin placentas compared to the normal cotwin placentas. Of these,
141 57 DEPs were upregulated and 176 DEPs were downregulated (Table S3).
142 Unsupervised hierarchical clustering of the DEPs revealed good separation between
143 the two groups (Figure 1D).

144 To deepen the biological insights into these DEPs, we utilized IPA software for
145 bioinformatics analysis. The core biofunction analysis of these DEPs was divided into
146 three categories. In “physiological system development and function” category, the
147 most significantly enriched item was “cardiovascular system development and
148 function”, which involved 52 DEPs. The other two main enriched subcategories were
149 “organismal survival” (number of DEPs in this function [n] = 66) and “organismal
150 development” (n = 71) (Figure 1E; Table S4). In addition, in “molecular and cellular
151 function” category, the top three enriched functions included “cell death and survival”,
152 “lipid metabolism”, and “molecular transport” (Figure S2A; Table S4). For “diseases
153 and disorders”, the DEPs were significantly related to “endocrine system disorders”,
154 “gastrointestinal disease”, and “metabolic disease” (Figure S2B; Table S4).
155 Additionally, IPA canonical pathway analysis identified oxidative phosphorylation,
156 mitochondrial dysfunction, and the Sirtuin signaling pathway as the top three
157 pathways that might be potentially affected in IUGR twin placentas (Figure S2C).

158 **Angiogenesis is significantly impaired in IUGR twin placentas**

159 Among the 52 DEPs involved in “cardiovascular system development and function”,
160 34 DEPs were enriched in the biological process of angiogenesis encompassed in this
161 biofunction, and the state of angiogenesis was predicted to be suppressed by IPA
162 (Figure 2A). Placental angiogenesis is crucial to villous development and placental
163 function. Any impairment in placental angiogenesis can lead to poor placentation,
164 decreased blood flow to the fetus, and various pregnancy complications [18]. To

165 confirm whether angiogenesis was altered in IUGR twin placentas, we assessed the
166 microvessel density (MVD) and vascular area density per sample following
167 immunostaining of CD34 as an endothelial cell marker. A significant decrease in
168 MVD was present in IUGR twin placentas, while the vascular area density was also
169 significantly lower in IUGR twin placentas than in the normal cotwins (Figure 2B–D).
170 Taken together, these data suggested that impaired placental angiogenesis in IUGR
171 twins might be responsible for the development of sIUGR. To further validate the
172 proteomic results, we selected 3 markers (*EFNB2*, *VIM*, and *METAP2*) for
173 immunohistochemistry analysis. The 3 markers were reported to play essential roles
174 in placental angiogenesis and fetal development [19–21]. As shown in Figure 2E–H,
175 the intensity of *VIM*, *EFNB2*, and *METAP2* immunoreactivity was significantly
176 lower in IUGR twin placentas than in normal cotwins, which was in line with TMT
177 proteomic results. Additionally, we performed qRT-PCR to explore their expression
178 changes at mRNA level. Similar to the proteomic data, *VIM*, *EFNB2*, and *METAP2*
179 mRNA expression levels were significantly downregulated in IUGR twin placentas
180 (Figure 2I–K).

181 ***MTDH* silencing inhibits HUVEC proliferation and migration**

182 Among the 34 DEPs related to angiogenesis, we also observed a significant decrease
183 in *MTDH* expression in IUGR twin placentas (Figure 3A–C). There is evidence that
184 *MTDH* participates in tumor angiogenesis [22,23], while its role in placental
185 angiogenesis remains unclear. During placental angiogenesis, endothelial cells
186 undergo proliferative, migratory, and morphological events to form a vessel network.
187 To investigate the causality between endothelial *MTDH* deficiency and sIUGR
188 development, the role of *MTDH* in the proliferation and migration of HUVECs was
189 explored. HUVECs were transfected with negative control siRNA (si-NC) and siRNA
190 against *MTDH* (si-*MTDH*). Transfection with si-*MTDH* markedly decreased *MTDH*
191 mRNA and protein levels (Figure 3D–F). The proliferation and migration abilities of
192 HUVECs were examined using an electrical impedance-based tool, the
193 xCELLigence® real-time cell analysis (RTCA) system, which enables continuous
194 monitoring of cell behaviors and allows for real-time assessment of multiple cell

195 functions. For the proliferation assay, cells treated with si-NC or si-*MTDH* were
196 seeded in the wells of an E-plate. Cells were cultured for 60 h, and the si-*MTDH*
197 group exhibited a significant reduction in proliferation ability (Figure 3G). Cell
198 migration was assessed using a CIM-16 plate with upper and lower chambers in each
199 well. The results revealed that *MTDH* interference obviously decreased HUVEC
200 migration ability compared with that of control cells (Figure 3H). To further confirm
201 the effect of *MTDH* deficiency on HUVEC migration in the horizontal direction, we
202 performed a wound healing assay. As expected, the wound in the
203 si-*MTDH*-transfected cell culture healed more slowly than that of the control group
204 (Figure 3I, J). In summary, these findings demonstrated that *MTDH* is vital to
205 HUVECs proliferation and migration.

206 **Knockdown of *MTDH* inhibits tube formation and spheroid sprouting in** 207 **HUVECs**

208 To further determine *MTDH*'s effect on placental angiogenesis, the 2-dimensional (2D)
209 tube formation assay and 3-dimensional (3D) spheroid sprouting assay were
210 conducted using HUVECs. As shown in **Figure 4A**, si-NC-transfected HUVECs
211 could form capillary-like structures in a few hours on Matrigel, while the tube
212 formation capacity was perturbed in the si-*MTDH* group. *MTDH* deficiency distinctly
213 impaired the number and area of tubes, the total tube length, as well as the number of
214 branching points (Figure 4B–E). Similarly, when embedded in 3D collagen I gels,
215 spheroids composed of si-NC-transfected HUVECs retained the ability to produce
216 capillary-like outgrowths, while only a few sprouts were formed in *MTDH*-depleted
217 HUVEC spheroids (Figure 4F). Compared to the control cells, the si-*MTDH* HUVECs
218 exhibited a significant reduction in cumulative sprout length (Figure 4G). Accordingly,
219 these data suggest that downregulation of *MTDH* inhibits placental angiogenesis.

220 ***MTDH* is required in placental development and fetal growth**

221 To verify whether *MTDH* is required in placental and fetal development, we knocked
222 down *MTDH* in HUVECs and performed RNA-seq analysis. Both the control and
223 si-*MTDH* groups had three biological replicates each. The correlation analysis based
224 on the overall RNA-seq data for each sample pair showed that the correlation

225 coefficient between intra-group samples was higher than that between inter-group
226 samples, indicating that samples within groups had strong resemblance in terms of
227 transcription pattern and the biological experimental operations were reliable and
228 reproducible, while the gene expression changed following MTDH interference.
229 **(Figure 5A)**. The top 50 protein-coding genes with significantly differential
230 expression (adjusted $P < 0.05$) were selected as candidates for further analysis (Table
231 S5). Among the 50 genes, 29 were upregulated and 21 were downregulated in the
232 si-*MTDH* group. The expression profiles of the 50 genes are presented in a heatmap
233 (Figure 5B). Further functional enrichment analysis revealed that 50 candidate genes
234 were associated with various biological processes, such as defense responses,
235 apoptotic processes, actin filament organization, negative regulation of cell
236 proliferation, and angiogenesis (Figure 5C). The interaction network of the 50
237 candidates is presented in Figure 5D.

238 Among the 50 candidates, we found quite a few genes previously reported to be
239 implicated in placental dysfunction and fetal growth restriction, including *PSG3*
240 (upregulation of *PSG3* in both maternal blood and IUGR placenta) [24,25], *CSF2*
241 (*Csf2*-deficient *mice* exhibit placental insufficiency and fetal growth retardation)
242 [26,27], *THSD7A* (higher expression of *THSD7A* is associated with low birth weight)
243 [28], *CYP11B1* (lower methylation levels of *CYP11B1* are found in preterm delivery
244 with reduced fetal growth) [29], and *PLCL1* (double-knockout *mice* for *Plcl1* and
245 *Plcl2* exhibit reduced litter events and litter size) [30]. These results further provide
246 support for the validity of our results. Interestingly, we also found several unreported
247 genes that may affect placental development and fetal growth, such as *IFITM2*,
248 *TMSB15A*, and *WAS*. These findings may help further the discovery of potential
249 biomarkers and therapeutic targets.

250

251 **Discussion**

252 Despite advances in perinatal care, IUGR remains a challenging problem faced by
253 obstetricians worldwide. Placental insufficiency and subsequent undernutrition and

254 hypoxia are considered to be the ultimate pathomechanisms that disturb fetal growth
255 [31]. However, the molecular regulatory mechanisms of IUGR have not been fully
256 elucidated due to genetic and maternal heterogeneity. In monochorionic twin
257 pregnancy, the IUGR twin and the normal cotwin have an identical genotype and
258 develop in the same uterus, making it an excellent model to investigate placental
259 disorders [32]. Proteins, which act as the ultimate executors of gene function, are vital
260 players within organisms in terms of functionality and structure [33]. Thus,
261 investigating the molecular basis for IUGR at the protein level is of paramount
262 importance to shed light on its clinical diagnosis and treatment. Based on the above
263 information, we sought to construct a comprehensive profile of the placental DEPs by
264 taking advantage of sIUGR twins. In this work, we performed TMT-based
265 comparative proteomic studies using placental samples of six sIUGR twin pairs from
266 the clinic. A total of 5481 unique proteins with high confidence were detected in
267 human placental tissues. Therein, 233 proteins were identified as DEPs between
268 IUGR twin and normal cotwin placentas, with 57 upregulated and 176 downregulated.

269 In the current work, numerous proteins relevant to embryonic development were
270 found to be dysregulated in IUGR twin placentas. As the interface of interaction and
271 communication between mother and fetus, the placenta is essential to embryo
272 development and, in particular, to fetal growth [34]. The aberrant expression of these
273 proteins in IUGR twin placentas implies that they may play key roles in impairing
274 fetal growth potential. In addition, a set of proteins that can modulate lipid
275 metabolism were detected in our study. Over the past few decades, lipid metabolism
276 during pregnancy has been highlighted as essential not only for optimal placental
277 development and function but also for proper intrauterine growth of the fetus [35].
278 Disrupted lipid metabolism may contribute to placental insufficiency and suboptimal
279 fetal growth, which is consistent with previous discoveries in singleton IUGR cases
280 [36,37]. In addition, proteins that are key players in molecular transport appeared
281 prominently among the top functional terms. In fact, the formation of an efficient
282 transport interface is the essence of the placenta, which allows the growing fetus to
283 fulfill its developmental demands from maternal circulation [34]. Alterations in

284 nutrient transporter expression have also been evidenced in IUGR placentas [38,39].

285 Notably, we found that 34 DEPs were implicated in angiogenesis. Adequate
286 angiogenesis ensures that placentas develop as highly vascularized organs, thereby
287 supporting the blood flow required for fetal growth [40]. Aberrant placental
288 vasculature has been identified in nearly all human pregnancy complications, further
289 confirming the importance of placental angiogenesis for normal pregnancy [41]. A
290 previous study discovered significantly decreased villus vascular density in placentas
291 of singleton IUGR [42]. Our results also confirmed that placental MVD and vascular
292 area density were significantly lower in smaller fetuses. These results together suggest
293 that impairment of placental angiogenesis may play key roles in the incidence and
294 development of IUGR. *MTDH*, also known as *AEG-1*, is implicated as an oncogene
295 [43,44]. According to our findings, *MTDH* was significantly downregulated in IUGR
296 twin placentas and located in intravillous capillary endothelial cells. In addition, we
297 verified that the function of *MTDH* is critical in placental angiogenesis, indicating that
298 decreased expression of *MTDH* may contribute to the pathogenesis of placental
299 dysfunction and fetal growth retardation. While our understanding of the molecular
300 mechanisms of IUGR has advanced significantly over the past few decades, there are
301 currently no reliable diagnostic biomarkers or targeted therapies available for this
302 disease in clinical practice [45,46]. Translational application of the candidate targets
303 identified in singleton IUGR pregnancies is very limited, probably mainly due to the
304 heterogeneity of the samples in these studies. Thus, *MTDH* identified in our
305 investigation using sIUGR twins may serve as a potential biomarker for early
306 prediction and accurate diagnosis of IUGR, as well as a novel target for future
307 treatment. In summary, our findings comprehensively described the proteomic
308 landscape of sIUGR twin placentas, which may provide reliable resources for
309 mechanistic studies of the core regulators involved in placental dysfunction and fetal
310 growth restriction.

311

312 **Materials and methods**

313 **Patients and clinical specimen collection**

314 Placental samples from 6 sIUGR twins were collected at Peking University Third
315 Hospital. Ultrasonography at 11–14 weeks was conducted to determine the
316 chorionicity, and postnatal placental examination was used to confirm it. sIUGR
317 refers to a monochorionic twin in which the estimated fetal weight (EFW) of one
318 fetus is lower than 10th percentile while the cotwin's is normal and the intertwin EFW
319 discordance is more than 25%. EFW was calculated based on Hadlock formula [47].
320 EFW discordance was calculated with this formula: (normal cotwin EFW–IUGR twin
321 EFW)/normal cotwin EFW. All participants underwent cesarean delivery, and the
322 samples were collected within 30 min. Samples were obtained from the maternal side
323 of the placental lobules within 2 cm of each umbilical cord insertion site, aiming to
324 reduce possible bias caused by the regional variations in placental gene expression
325 associated with the sampling sites [48,49]. The placental biopsies were excised in
326 areas free of macroscopic lesions of calcification or infarction after removing the
327 maternal deciduas and fetal membranes. The biopsy was washed in PBS for blood
328 removal. A portion of the sample was stored at –80°C after freezing in liquid nitrogen.
329 The rest was fixed in 10% formalin solution followed by embedding in paraffin.

330 **Protein extraction, digestion, and TMT labeling**

331 Placental tissues were lysed using 7 M urea with 1% (w/v) dithiothreitol (DTT), 2 M
332 thiourea, and 1% (v/v) protease inhibitor cocktail. Equal amounts of protein (100
333 µg/sample) were used for subsequent processing. 1 M DTT was used for peptide
334 reduction at 56°C for 30 min and 1 M iodoacetamide for alkylation at room
335 temperature for 30 min in darkness. Samples were diluted with 25 mM (pH 8.2)
336 Tris-HCl and 0.1 M CaCl₂ until the final concentration of urea was 1 mM. Trypsin
337 (Catalog No. V5111, Promega, Madison, WI) was used to digest proteins for 12 h.
338 The resulting peptides were desalted on Sep-Pak C18 columns (Waters, Altrincham
339 Road, Wilmslow, UK), and then labeled with two sets of six-plex TMT reagents
340 (Catalog No. 90062, Thermo Fisher Scientific, Waltham, MA). Each 6 isobaric
341 labeled samples within the same set were combined and vacuum dried for further
342 analysis.

343 **LC-MS/MS**

344 The peptide mixture was separated into 10 fractions by high pH RPLC using BEH
345 C18 columns (1.7 μm , 1.0 mm \times 150 mm) attached to the H-Class System (Waters).
346 The second-dimensional liquid chromatography separation of the peptides was
347 conducted on the EkspertTM nano LC 415 instrument (AB Sciex, Toronto, Canada).
348 The peptides were eluted using 2% acetonitrile with 0.1% formic acid as buffer A and
349 98% acetonitrile with 0.1% formic acid as buffer B with a gradient of 100 min. The
350 eluted peptides were subsequently analyzed using TripleTOF 5600+ mass
351 spectrometer (AB Sciex). Data were obtained in positive ion mode. For TOF-MS scan,
352 the mass range was set as 350–1500 m/z . The MS/MS scan was carried out with a
353 mass range of 100–1500 m/z .

354 **Data analysis**

355 The raw data were analyzed by using the MaxQuant software (Version 1.5.2.8) [50]
356 and the human UniProt reference protein sequences [51] to generate initial
357 spectra-peptide matches and quantification values. The search was performed with the
358 following parameters: enzyme, trypsin/p; max missed cleavages, 2; 0.1 Da for first
359 search mass tolerance; 0.01 Da for main search mass tolerance; variable modifications,
360 acetylation (N-term) and oxidation (M); fixed modification, carbamidomethyl (C).
361 Protein identification requires at least one unique peptide. False discovery rate (FDR)
362 was 0.05 for both peptide and protein identification. Then, the MaxQuant results were
363 further processed by the MaxReport software [52] to correct and optimize the
364 quantitative results. In brief, the reporting intensity of each isobaric label was
365 corrected by an impurity correction matrix. Additionally, each label (sample) was
366 normalized by the total intensity. Then, the relative protein expressions were
367 calculated by the Libra algorithm [53]. Finally, DEPs were determined by $P < 0.05$
368 and $|\text{FC}| > 1.3$. The MaxReport quantification workflow was also successfully tested
369 by using a benchmark dataset (PXD000001) to quantify the spiked reference proteins.
370 Additionally, all of the samples were harvested and processed in the same
371 experimental period. Due to the limited number of TMT labels, these samples were
372 labeled separately and loaded into the mass spectrometer in a sequential process.

373 Comparison of the average intensities and unique peptides between the two six-plex
374 TMT experiments indicated that there was a minor batch effect between the two
375 groups, as the Pearson correlation coefficient values for intensities and peptides were
376 0.96 and 0.98, respectively. Considering only two sequential batches in this study, we
377 did not perform such correction. The global protein expression patterns of sIUGR
378 twin placentas were illustrated using histograms and volcano plots in the R package
379 (version 3.5.2). Hierarchical cluster analysis of the DEPs was performed with MeV
380 software (version 4.9.0). We used IPA software (QIAGEN, Redwood City, CA) to
381 identify the biofunctions that were significantly associated with the DEPs.
382 Specifically, the list of DEPs, containing gene symbols, fold changes and *P* values,
383 was uploaded into IPA software for core analysis. The core analysis included
384 enrichment of diseases and functions, canonical pathways, and networks. The core
385 analysis was conducted with the setting of direct and indirect relationships between
386 focused genes based on the human section of “Ingenuity Knowledge Base”, which
387 was a manually curated database of biological interactions and functional annotations.

388 **Immunohistochemistry**

389 After deparaffinization, antigen retrieval and endogenous peroxide blocking, the
390 sections (5 μ m in thickness) were incubated with primary anti-CD34 antibody
391 (Catalog No. ZM-0046, ZSGB-BIO, Beijing, China), anti-EFNB2 antibody (1:50;
392 Catalog No. HPA008999, Atlas Antibodies, Bromma, Sweden), anti-METAP2
393 antibody (1:3000; Catalog No. HPA019095, Atlas Antibodies), anti-VIM antibody
394 (Catalog No. ZM-0260, ZSGB-BIO) and anti-MTDH antibody (1:150; Catalog No.
395 ab124789, Abcam, Cambridge, UK). After incubating with secondary antibodies, the
396 sections were stained with diaminobenzidine solution (Catalog No. ZLI-9018,
397 ZSGB-BIO). The expression level of the target genes was assessed with Image-Pro
398 Plus (Media Cybernetics, Rockville, MD).

399 **MVD and vascular area density**

400 Using CD34 as an endothelial cell marker, the MVD was used to evaluate placental
401 angiogenesis by measuring the immunostaining of CD34 in placental sections. Briefly,
402 the number of CD34-positive vessels was counted under a magnification of 400 \times in 5

403 nonconsecutive fields by two observers who were blinded to the control and case
404 groups. The mean value of the 5 fields was expressed as the MVD. The vascular area
405 density was evaluated as follows: 5 images per slide with a magnification of $\times 200$
406 were captured by NanoZoomer-SQ (Catalog No. C13140-01, Hamamatsu, Shizuoka,
407 Japan) and NDP.view2 software (Hamamatsu). Image-Pro Plus (Media Cybernetics)
408 was used for measurement of the vascular area and the villous area. The mean of the
409 percentage of vascular area in villous area in 5 images was defined as the vascular
410 area density.

411 **RNA extraction and qRT-PCR**

412 RNA was extracted using TRIzol (Catalog No. 15596018, Thermo Fisher Scientific),
413 and then reverse-transcribed into cDNA. qRT-PCR was conducted with the SYBRTM
414 Green Master Mix reagent (Catalog No. A25742, Thermo Fisher Scientific). Internal
415 reference gene was *glyceraldehyde-3-phosphate dehydrogenase (GAPDH)*. All
416 experiments were replicated three times independently. Sangon Biotech Corporation
417 (Shanghai, China) supplied the primers (Table S6).

418 **Cell culture**

419 Immortalized HUVECs were a generous gift from Peking University Third Hospital
420 Medical Research Center. HUVECs were cultured in DMEM/F-12 medium (Catalog
421 No. C11330500BT, Thermo Fisher Scientific) containing 1% penicillin/streptomycin
422 (Catalog No. V900929, Sigma-Aldrich, St. Louis, MO) as well as 10% fetal bovine
423 serum (FBS) (Catalog No. 10099141, Thermo Fisher Scientific) at 37°C with 5% CO₂.
424 HUVECs were authenticated with short tandem repeat analysis.

425 **Cell transfection**

426 Transient transfection of HUVECs with siRNA was performed at 70% confluence in
427 six-well plates using Lipofectamine 3000 (Catalog No. L3000015, Thermo Fisher
428 Scientific). *MTDH* siRNA sequences were as follows: sense, (5'–3')
429 GGAACCAAUCCUGAUGAUTT; antisense (5'–3')
430 AUCAUCAGGAAUUGGUUCCTT. The siRNA was synthesized by GenePharma
431 (Shanghai, China).

432 **Western blotting**

433 Proteins (20 mg for each sample) were electrophoresed on 8% SDS-PAGE gels and
434 then transferred to polyvinylidene fluoride membranes (Catalog No. IPVH00010,
435 Millipore Bedford, MA). The membranes were blocked in 5% nonfat dry milk
436 followed by incubating with anti-MTDH antibody (1:10,000; Catalog No. ab124789,
437 Abcam) and anti-GAPDH antibody (1:5000; Catalog No. ab8245, Abcam) overnight
438 at 4°C. After incubating with secondary antibodies, the bands were revealed with an
439 enhanced ECL Kit (Catalog No. BF06053-500, Biodragon, Beijing, China) and
440 analyzed by ImageJ (National Institutes of Health, NIH) using GAPDH as the loading
441 control.

442 **Real-time cell proliferation and migration assays**

443 The RTCA analyzer (ACEA Biosciences, San Diego, CA) was used to examine cell
444 proliferation and migration abilities. The cell proliferation assay was carried out on
445 the E-plate with each well consisting of 5×10^3 cells treated with si-*MTDH* or
446 si-NC. The impedance of each well, expressed as the cell index (CI), was
447 automatically measured every 30 min for 60 h. The migration assay was performed in
448 a CIM-16 plate. A total of 2×10^4 transfected cells were seeded into the upper
449 chamber with serum-free medium, while it was complete medium in the lower
450 chamber. Scans were run with sweeps every 15 min for 60 h. The impedance of each
451 well was also represented by the CI.

452 **Wound healing assay**

453 In 6-well plates, 5×10^5 HUVECs transfected with either si-*MTDH* or si-NC were
454 seeded per well. When cells reached confluence, scratches were made with 200- μ l
455 pipette tips. Afterwards, serum-free medium was used for cell culture, and images
456 were captured every 12 h for a total of 24 h. The NIH ImageJ software was applied to
457 analyze the cell migration distance.

458 **Tube formation assay**

459 In 96-well plates, 60 μ l of Matrigel (Catalog No. 356234, BD Biosciences, Bedford,
460 MA) was placed in each well, which was then solidified at 37°C for 30 min.
461 Transfected HUVECs (2×10^4 /well) were seeded into Matrigel-coated wells and
462 cultured for 8 h. After that, the medium was discarded, and the cells were labeled with

463 2 μ M calcein AM fluorescent dye (Catalog No. ab141420, Abcam) at 37°C for 20 min.
464 The LeicaDMI4000B inverted microscope was used to observe the capillary-like
465 structures, and images were taken using a Leica DFC345FX camera. The number and
466 area of the formed tubes, the number of junctions, as well as the total branching
467 length were quantified using ImageJ software (NIH). Experiments were performed 3
468 times independently.

469 **Spheroid sprouting assay**

470 As previously described, we performed the 3D sprouting assay [54]. HUVECs were
471 harvested after 24 h of transfection with either si-*MTDH* or si-NC to generate
472 endothelial cell spheroids. Briefly, HUVECs (1×10^3 /well) were added into
473 nonadherent round-bottom 96-well plates, and the cells spontaneously formed a single
474 EC spheroid in each well within 24 h. The spheroids were then embedded in collagen
475 gel and cultured for 48 h. A LeicaDMI4000B inverted microscope was used to
476 observe the spheroids after labeling with calcein AM. ImageJ software (NIH) was
477 used to measure all sprouts originating from each spheroid. The cumulative sprout
478 length of 10 spheroids were compared between the 2 groups. The experiments were
479 replicated 3 times independently.

480 **RNA-seq and data analysis**

481 RNA was isolated and quality controlled. The cDNA libraries of transfected HUVECs
482 were constructed and purified, followed by sequencing on Illumina NovaSeq platform.
483 Clean reads were achieved by processing raw data with in-house Perl scripts. HISAT2
484 was used for reads alignment and featureCounts for counting reads. DESeq2 was
485 applied for differentially expressed genes identification (adjusted $P < 0.05$). DAVID
486 v6.8 was used for gene ontology (GO) analysis. GeneMANIA was carried out to
487 construct protein-protein interaction network.

488 **Statistical analysis**

489 Proliferation and migration curves were estimated by two-way ANOVA using SPSS
490 software version 25.0. Paired t -test was applied to compare the differences between
491 IUGR twins and the normal cotwins. All other data comparisons were conducted with
492 Student's t -test. $P < 0.05$ was considered statistically significant.

493

494 **Ethical statement**

495 Ethical approval of our study was achieved from the Ethics Committee of the Peking
496 University Third Hospital (IRB00006761-2016145). Prior to placental samples
497 collection, written informed consent was obtained from participants.

498

499 **Data availability**

500 The placental proteomic data of sIUGR twins have been uploaded to the iProX
501 database (<https://www.iprox.org/>) [55], and are accessible with the dataset identifier
502 IPX0004712000. The RNA-seq data of HUVECs have been submitted to the Genome
503 Sequence Archive (GSA: HRA002656) at <https://ngdc.cncb.ac.cn/gsa-human/> [56].

504

505 **Competing interests**

506 All authors declare no competing interests.

507

508 **Acknowledgments**

509 Our investigation was supported by the National Natural Science Foundation of China
510 (Grant Nos. 81971399 and 82171661).

511

512 **References**

- 513 [1] Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR):
514 epidemiology and etiology. *Pediatr Endocrinol Rev* 2009;6:332–6.
- 515 [2] Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and
516 mortality among very-low-birth-weight neonates with intrauterine growth
517 restriction. *Am J Obstet Gynecol* 2000;182:198–206.
- 518 [3] Barker DJ. The fetal and infant origins of adult disease. *BMJ* 1990;301:1111.
- 519 [4] Regnault TR, Galan HL, Parker TA, Anthony RV. Placental development in
520 normal and compromised pregnancies-- a review. *Placenta*. 2002;23:S119–29.

- 521 [5] Chaddha V, Viero S, Huppertz B, Kingdom J. Developmental biology of the
522 placenta and the origins of placental insufficiency. *Semin Fetal Neonatal Med*
523 2004;9:357–69.
- 524 [6] Gagnon R. Placental insufficiency and its consequences. *Eur J Obstet Gynecol*
525 *Reprod Biol* 2003;110:S99–107.
- 526 [7] Neerhof MG, Thaete LG. The fetal response to chronic placental insufficiency.
527 *Semin Perinatol* 2008;32:201–5.
- 528 [8] Bennasar M, Eixarch E, Martinez JM, Gratacós E. Selective intrauterine growth
529 restriction in monochorionic diamniotic twin pregnancies. *Semin Fetal Neonatal*
530 *Med* 2017;22:376–82.
- 531 [9] Lopriore E, Pasman SA, Klumper FJ, Middeldorp JM, Walther FJ, Oepkes D.
532 Placental characteristics in growth-discordant monochorionic twins: a matched
533 case-control study. *Placenta* 2012;33:171–4.
- 534 [10] Kalafat E, Thilaganathan B, Papageorgiou A, Bhide A, Khalil A. Significance
535 of placental cord insertion site in twin pregnancy. *Ultrasound Obstet Gynecol*
536 2018;52:378–84.
- 537 [11] Gou C, Li M, Zhang X, Liu X, Huang X, Zhou Y, et al. Placental characteristics
538 in monochorionic twins with selective intrauterine growth restriction assessed by
539 gradient angiography and three-dimensional reconstruction. *J Matern Fetal*
540 *Neonatal Med* 2017;30:2590–5.
- 541 [12] Chu S, Mao Q, Shapiro S, De Paepe ME. Placental endoglin levels in
542 diamniotic-mono chorionic twin gestations: correlation with clinical and placental
543 characteristics. *Placenta* 2013;34:261–8.
- 544 [13] Schrey S, Kingdom J, Baczyk D, Fitzgerald B, Keating S, Ryan G, et al. *Leptin* is
545 differentially expressed and epigenetically regulated across monochorionic twin
546 placenta with discordant fetal growth. *Mol Hum Reprod* 2013;19:764–72.
- 547 [14] Nevo O, Many A, Xu J, Kingdom J, Piccoli E, Zamudio S, et al. Placental
548 expression of soluble *fms-like tyrosine kinase 1* is increased in singletons and
549 twin pregnancies with intrauterine growth restriction. *J Clin Endocrinol Metab*
550 2008;93:285–92.
- 551 [15] Zhang GL, He ZM, Shi XM, Gou CY, Gao Y, Fang Q. Discordant *HIF1A*
552 mRNA levels and oxidative stress in placental shares of monochorionic twins
553 with selective intra-uterine growth restriction. *Placenta* 2015;36:297–303.
- 554 [16] Gou C, Liu X, Shi X, Chai H, He ZM, Huang X, et al. Placental expressions of
555 *CDKN1C* and *KCNQ1OT1* in monozygotic twins with selective intrauterine
556 growth restriction. *Twin Res Hum Genet* 2017;20:389–94.
- 557 [17] Roifman M, Choufani S, Turinsky AL, Drewlo S, Keating S, Brudno M, et al.
558 Genome-wide placental DNA methylation analysis of severely growth-discordant
559 monochorionic twins reveals novel epigenetic targets for intrauterine growth
560 restriction. *Clin Epigenetics* 2016;8:70.

- 561 [18] Reynolds LP, Redmer DA. Angiogenesis in the placenta. *Biol Reprod*
562 2001;64:1033–40.
- 563 [19] Antfolk D, Sjoqvist M, Cheng F, Isoniemi K, Duran CL, Rivero-Muller A, et al.
564 Selective regulation of Notch ligands during angiogenesis is mediated by
565 *vimentin*. *Proc Natl Acad Sci U S A* 2017;114:E4574–81.
- 566 [20] Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic
567 interaction between embryonic arteries and veins revealed by *ephrin-B2* and its
568 receptor *Eph-B4*. *Cell* 1998;93:741–53.
- 569 [21] Yeh JJ, Ju R, Brdlik CM, Zhang W, Zhang Y, Matyskiela ME, et al. Targeted
570 gene disruption of methionine aminopeptidase 2 results in an embryonic
571 gastrulation defect and endothelial cell growth arrest. *Proc Natl Acad Sci U S A*
572 2006;103:10379–84.
- 573 [22] Liu Y, Kong X, Li X, Li B, Yang Q. Knockdown of *metadherin* inhibits
574 angiogenesis in breast cancer. *Int J Oncol* 2015;46:2459–66.
- 575 [23] Long M, Dong K, Gao P, Wang X, Liu L, Yang S, et al. Overexpression of
576 *astrocyte-elevated gene-1* is associated with cervical carcinoma progression and
577 angiogenesis. *Oncol Rep* 2013;30:1414–22.
- 578 [24] Whitehead CL, Walker SP, Ye L, Mendis S, Kaitu'u-Lino TJ, Lappas M, et al.
579 Placental specific mRNA in the maternal circulation are globally dysregulated in
580 pregnancies complicated by fetal growth restriction. *J Clin Endocrinol Metab*
581 2013;98:E429–36.
- 582 [25] McMinn J, Wei M, Schupf N, Cusmai J, Johnson EB, Smith AC, et al.
583 Unbalanced placental expression of imprinted genes in human intrauterine
584 growth restriction. *Placenta* 2006;27:540–9.
- 585 [26] Sferruzzi-Perri AN, Macpherson AM, Roberts CT, Robertson SA. *Csf2* null
586 mutation alters placental gene expression and trophoblast glycogen cell and giant
587 cell abundance in *mice*. *Biol Reprod* 2009;81:207–21.
- 588 [27] Robertson SA, Roberts CT, Farr KL, Dunn AR, Seamark RF. Fertility
589 impairment in granulocyte-macrophage colony-stimulating factor-deficient *mice*.
590 *Biol Reprod* 1999;60:251–61.
- 591 [28] Lambertini L, Li Q, Ma Y, Zhang W, Hao K, Marsit C, et al. Placental imprinted
592 gene expression mediates the effects of maternal psychosocial stress during
593 pregnancy on fetal growth. *J Dev Orig Health Dis* 2019;10:196–205.
- 594 [29] Chen X, Bai G, Scholl TO. Spontaneous preterm delivery, particularly with
595 reduced fetal growth, is associated with DNA hypomethylation of tumor related
596 genes. *J Pregnancy Child Health* 2016;3:215.
- 597 [30] Matsuda M, Tsutsumi K, Kanematsu T, Fukami K, Terada Y, Takenawa T, et al.
598 Involvement of phospholipase C-related inactive protein in the mouse
599 reproductive system through the regulation of gonadotropin levels. *Biol Reprod*
600 2009;81:681–9.

- 601 [31] Audette MC, Kingdom JC. Screening for fetal growth restriction and placental
602 insufficiency. *Semin Fetal Neonatal Med* 2018;23:119–25.
- 603 [32] Li W, Chung CYL, Wang CC, Chan TF, Leung MBW, Chan OK, et al.
604 Monochorionic twins with selective fetal growth restriction: insight from
605 placental whole-transcriptome analysis. *Am J Obstet Gynecol*
606 2020;223:749.e1–16.
- 607 [33] Li X, Wang W, Chen J. Recent progress in mass spectrometry proteomics for
608 biomedical research. *Sci China Life Sci* 2017;60:1093–113.
- 609 [34] Maltepe E, Fisher SJ. Placenta: the forgotten organ. *Annu Rev Cell Dev Biol*
610 2015;31:523–52.
- 611 [35] Herrera E, Ortega-Senovilla H. Lipid metabolism during pregnancy and its
612 implications for fetal growth. *Curr Pharm Biotechnol* 2014;15:24–31.
- 613 [36] Chabrun F, Huetz N, Dieu X, Rousseau G, Bouzille G, Chao de la Barca JM, et
614 al. Data-mining approach on transcriptomics and methylomics placental analysis
615 highlights genes in fetal growth restriction. *Front Genet* 2019;10:1292.
- 616 [37] Paules C, Youssef L, Miranda J, Crovetto F, Estanyol JM, Fernandez G, et al.
617 Maternal proteomic profiling reveals alterations in lipid metabolism in late-onset
618 fetal growth restriction. *Sci Rep* 2020;10:21033.
- 619 [38] Zur RL, Kingdom JC, Parks WT, Hobson SR. The placental basis of fetal growth
620 restriction. *Obstet Gynecol Clin North Am* 2020;47:81–98.
- 621 [39] Chassen S, Jansson T. Complex, coordinated and highly regulated changes in
622 placental signaling and nutrient transport capacity in IUGR. *Biochim Biophys*
623 *Acta Mol Basis Dis* 2020;1866:165373.
- 624 [40] Huppertz B, Peeters LL. Vascular biology in implantation and placentation.
625 *Angiogenesis* 2005;8:157–67.
- 626 [41] Mayhew TM, Charnock-Jones DS, Kaufmann P. Aspects of human fetoplacental
627 vasculogenesis and angiogenesis. III. Changes in complicated pregnancies.
628 *Placenta* 2004;25:127–39.
- 629 [42] Chen CP, Bajoria R, Aplin JD. Decreased vascularization and cell proliferation
630 in placentas of intrauterine growth-restricted fetuses with abnormal umbilical
631 artery flow velocity waveforms. *Am J Obstet Gynecol* 2002;187:764–9.
- 632 [43] Manna D, Sarkar D. Multifunctional role of *astrocyte elevated gene-1 (AEG-1)*
633 in cancer: focus on drug resistance. *Cancers (Basel)* 2021;13.
- 634 [44] Dhiman G, Srivastava N, Goyal M, Rakha E, Lothion-Roy J, Mongan NP, et al.
635 Metadherin: a therapeutic target in multiple cancers. *Front Oncol* 2019;9:349.
- 636 [45] Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al.
637 FIGO (international federation of gynecology and obstetrics) initiative on fetal
638 growth: best practice advice for screening, diagnosis, and management of fetal
639 growth restriction. *Int J Gynaecol Obstet* 2021;152:3–57.

- 640 [46] Smith GCS. Universal screening for foetal growth restriction. Best Pract Res
641 Clin Obstet Gynaecol 2018;49:16–28.
- 642 [47] Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal
643 weight with the use of head, body, and femur measurements - a prospective-study.
644 Am J Obstet Gynecol 1985;151:333–7.
- 645 [48] Wyatt SM, Kraus FT, Roh CR, Elchalal U, Nelson DM, Sadovsky Y. The
646 correlation between sampling site and gene expression in the term human
647 placenta. Placenta 2005;26:372–9.
- 648 [49] Sood R, Zehnder JL, Druzin ML, Brown PO. Gene expression patterns in human
649 placenta. Proc Natl Acad Sci U S A 2006;103:5478–83.
- 650 [50] Cox J, Mann M. MaxQuant enables high peptide identification rates,
651 individualized p.p.b.-range mass accuracies and proteome-wide protein
652 quantification. Nat Biotechnol 2008;26:1367–72.
- 653 [51] Magrane M. UniProt knowledgebase: a hub of integrated protein data. Database
654 (Oxford) 2011;2011:bar009.
- 655 [52] Zhou T, Li C, Zhao W, Wang X, Wang F, Sha J. MaxReport: An enhanced
656 proteomic result reporting tool for MaxQuant. PLoS One 2016;11:e0152067.
- 657 [53] Deutsch EW, Mendoza L, Shteynberg D, Farrah T, Lam H, Tasman N, et al. A
658 guided tour of the Trans-Proteomic Pipeline. Proteomics 2010;10:1150–9.
- 659 [54] Cattaneo MG, Lucci G, Vicentini LM. Oxytocin stimulates *in vitro* angiogenesis
660 via a Pyk-2/Src-dependent mechanism. Exp Cell Res 2009;315:3210–9.
- 661 [55] Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome
662 resource. Nucleic Acids Res 2019;47:D1211–7.
- 663 [56] Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, et al. The genome sequence
664 archive family: toward explosive data growth and diverse data types. Genomics
665 Proteomics Bioinformatics 2021;19:578–83.
- 666

667 **Figure Legends**

668 **Figure 1 Identification and biofunction analysis of DEPs in IUGR twin**
669 **placentas**

670 **A.** Proteomic workflow for placental tissues from normal cotwins and IUGR twins.
671 Twelve samples from 6 sIUGR pregnancies were enrolled in this study and labeled
672 with two sets of six-plex TMT reagents. **B.** Histogram plot showing the \log_2 FC
673 distribution of all identified proteins. **C.** Volcano plot of DEPs between IUGR twin
674 placentas and normal cotwin placentas. DEPs were selected with $P < 0.05$ and $|FC| >$
675 1.3. Red spots indicate the downregulated DEPs, blue spots represent the upregulated
676 DEPs, and gray spots indicate proteins without significantly different expression. **D.**
677 Heatmap of the DEPs identified in IUGR twin placentas. Proteins are represented by
678 rows, and samples by columns. **E.** Functional analysis of the DEPs in IUGR twin
679 placentas using IPA software. DEPs, differentially expressed proteins; IUGR,
680 intrauterine growth restriction; sIUGR, selective IUGR; RPLC, reverse-phase liquid
681 chromatography; FC, fold change; LC-MS/MS, liquid chromatography tandem mass
682 spectrometry; N, normal cotwin; I, IUGR twin; TMT, tandem mass tag; IPA,
683 ingenuity pathway analysis.

684

685 **Figure 2 Impairment of angiogenesis in IUGR twin placentas**

686 **A.** IPA identified the “angiogenesis” annotation to be affected in IUGR twin placentas.
687 **B.** Immunostaining of CD34 in human placentas from IUGR twins and normal
688 cotwins. CD34 is limited to endothelial cells. Scale bar, 50 μm . **C.** Placental MVD in
689 IUGR twins and normal cotwins. **D.** Placental vascular area density in IUGR twins
690 and normal cotwins. **E.** Immunohistochemical images of *EFNB2*, *VIM*, and *METAP2*
691 in placental shares from IUGR twins and normal cotwins. Scale bar, 100 μm . **F–H.**
692 *EFNB2*, *VIM*, and *METAP2* immunostaining intensity per tissue area is represented
693 by the fold-decrease relative to the normal control mean. **I–K.** qRT-PCR analysis
694 showed that the *EFNB2*, *VIM*, and *METAP2* transcriptional levels were significantly
695 lower in placentas of IUGR twins compared with normal cotwins. All data are shown

696 as mean \pm SD with 6 samples per group. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.
697 MVD, microvessel density; NC, negative control; SD, standard deviation.

698

699 **Figure 3 *MTDH* expression is downregulated in IUGR twin placentas, and**
700 ***MTDH* knockdown impairs HUVECs proliferation and migration**

701 **A.** *MTDH* mRNA levels in IUGR twin placentas (n = 6) and normal cotwin placentas
702 (n = 6) by qRT-PCR analysis. **B.** *MTDH* expression in placental shares of IUGR twins
703 and normal cotwins by immunohistochemistry. Scale bar, 100 μ m. **C.** *MTDH*
704 immunostaining intensity in IUGR twin and normal cotwin placentas (n = 6 in each
705 group). **D–F.** After transfection for 48 h, the interference efficiency of siRNA
706 targeting *MTDH* in HUVECs was evaluated by qRT-PCR (**D**) and western blotting
707 (**E**). The relative intensity of *MTDH* levels was evaluated by ImageJ from three
708 independent experiments (**F**). **G.** Proliferation curves showed that *MTDH* knockdown
709 greatly inhibited HUVECs proliferation. Two-way ANOVA was used for data analysis.
710 **H.** Migration curves revealed that *MTDH* knockdown greatly inhibited HUVECs
711 migration. Two-way ANOVA was used for data analysis. **I–J.** Knockdown of *MTDH*
712 in HUVECs decreased the rate of wound closure. Scale bar, 100 μ m. All experiments
713 had 3 replicates with results shown as mean \pm SD. *, $P < 0.05$; **, $P < 0.01$; ***, $P <$
714 0.001. ANOVA, analysis of variance.

715

716 **Figure 4 *MTDH* knockdown inhibits HUVECs tube formation and spheroid**
717 **sprouting**

718 **A.** HUVECs were harvested 48 h after transfection with si-NC or si-*MTDH* and then
719 plated in Matrigel-coated wells. After 8 h, HUVEC tube formation was observed
720 under a LeicaDMI4000B microscope and photographed. Scale bar, 100 μ m. **B–E.**
721 Quantification of the number of tubes (**B**), total tube length (**C**), total tube area (**D**),
722 and number of branching points (**E**) in the si-*MTDH* group and the si-NC group using
723 ImageJ software. The results were from three independent assays. **F.** si-NC or
724 si-*MTDH* transfected HUVECs spheroids were photographed 48 h later after
725 embedding in collagen gels. Scale bar, 100 μ m. **G.** ImageJ software was used to

726 quantify the cumulative sprout length in the si-*MTDH* group and the si-NC group. All
727 data are expressed as mean \pm SD from 3 experiments. **, $P < 0.01$; ***, $P < 0.001$.

728

729 **Figure 5 RNA-seq analysis of HUVECs following *MTDH* interference**

730 **A.** Correlation coefficient analysis based on RNA-seq data for each sample pair.

731 Three replicates per condition. **B.** Heatmap of the top 50 differentially expressed

732 protein-coding genes between si-*MTDH* group and si-NC group. Genes are

733 represented by rows, and samples by columns. **C.** Bubble plot depicting biological

734 process enrichment for 50 candidates by gene ontology. **D.** Interaction network of the

735 50 candidate genes. The network was constructed by GeneMANIA and visualized

736 using Cytoscape 3.7.2.

737

738

739

740 **Supplementary material**

741 **Figure S1 Clinical characteristics and placental histopathology of sIUGR twins**

742 **A–B.** Representative images of ultrasound biometric measurements of the normal

743 cotwin (**A**) and the IUGR twin (**B**) from a sIUGR pregnancy, including BPD, HC, AC,

744 and FL. **C.** Ultrasound estimated fetal weight of the normal cotwins and the IUGR

745 twins from six pairs of sIUGR pregnancies throughout gestation were plotted on the

746 fetal growth curve. **D.** Birth weight of the normal cotwins and the IUGR twins ($n = 6$

747 in each group). **E.** Normal placental parenchyma from the normal cotwin. Scale bar,

748 100 μm . **F.** Distal villous hypoplasia in the IUGR twin placenta. Scale bar, 100 μm . **G.**

749 Increased fibrin deposition (arrow) in the IUGR twin placenta. Scale bar, 100 μm . **H.**

750 Increased syncytial knots (arrow) in the IUGR twin placenta. Scale bar, 100 μm . **I.** A

751 representative image of sIUGR twin placenta after dye injection. Placental sharing

752 was indicated by the white dotted line. Velamentous cord insertion was observed in

753 the IUGR twin. ***, $P < 0.001$. BPD, biparietal diameter; HC, head circumference;

754 AC, abdominal circumference; FL, femur length.

755

756 **Figure S2 Bioinformatic analysis of the DEPs in IUGR twin placentas by IPA**
757 **software**

758 **A.** DEPs significantly enriched in the “molecular and cellular function” category. **B.**
759 DEPs significantly enriched in the “disease and disorder” category. **C.** Canonical
760 pathway analysis of the DEPs.

761

762 **Table S1 Clinical features of 6 sIUGR twins**

763

764 **Table S2 Detailed information on 5481 nonredundant proteins identified in**
765 **siIUGR twin placentas**

766

767 **Table S3 Detailed information on 233 DEPs in IUGR twin placentas**

768






769 **Table S4 Detailed information on the biofunction analysis by IPA**

770


771 **Table S5 The top 50 differentially expressed protein-coding genes between the**
772 **si-*MTDH* group and the si-NC group**

773


774 **Table S6 Primers used for qRT-PCR**

A**B****C****D****E**


A




B




C




D




E




F




G




H




I




















J






K







A**B****C****D**